Job Description

At TCR² Therapeutics Inc, our inclusive and diverse team is passionate about curing cancer. We are a clinical-stage immunotherapy company pioneering the development of novel T cell therapies. Our two lead cell product candidates are being studied in Phase 1/2 trials: TC-210 for solid tumors and TC-110 for hematological malignancies. Our research efforts focus on broadening our pipeline with a series of next-generation enhancements that may further improve clinical outcomes. We are headquartered in Cambridge, Massachusetts and have a clinical manufacturing facility in Stevenage, UK. This role is located in Cambridge, MA.

We are looking for a Principal Scientist/Associate Director who will report to the Sr. Director of Pharmacology. We are seeking an experienced in vivo pharmacologist with a strong background in cancer immunotherapy to support pipeline progression across TCR2’s portfolio of targeted TRuC T cell therapies for oncology. The successful applicant will have extensive hands-on experience with mouse tumor model development and ex vivo immune profiling, along with a demonstrated ability to lead and mentor a scientific team. The qualified candidate is a highly motivated, interactive and creative scientist who will oversee the design and execution of xenograft and syngeneic mouse tumor model studies that will guide lead candidate selection and demonstrate preclinical proof-of-concept for enhancement strategies. The successful candidate will collaborate cross-functionally and effectively present scientific results to multidisciplinary teams and company leadership.

Responsibilities:

Oversee the design and execution of in vivo pharmacology studies aimed at identifying lead candidates for novel TRuC T cell therapies and evaluating enhancements concepts
Lead hands-on from the lab bench to guide, train, and coach a small scientific team
Develop target and indication relevant xenogeneic and syngeneic mouse tumor models to evaluate TRuC T cell efficacy, mechanism of action, dose-response and biodistribution
Perform ex vivo assessments of TRuC T cell functionality and behavior using various technologies including: flow cytometry, Nanostring, RNA-seq, and IHC
Develop novel assays for immunoprofiling of TRuC T cells
Lead cross-functional collaborations to achieve optimal in vivo study designs that deliver critical data to guide program decision-making
Serve as the In Vivo Pharmacology Lead on project teams, setting the strategy for in vivo model selection, study design/endpoints, and data intrepretation
Present in vivo research findings to internal and external audiences; author manuscripts for publication of research findings
Participate in IND document preparation as needed

Requirements:

Ph.D.* in biology-related discipline with 5+ years of post-Ph.D. research experience, in the in vivo evaluation of cancer immunotherapies; 2+ years of industry experience with adoptive T cell therapies required
Experienced people manager and leader of cross-functional teams
Highly proficient in the technical performance of xenogeneic and syngeneic mouse tumor model studies (hematologic and solid tumors) with extensive experience in model development and validation
Well-versed in T cell therapy pharmacokinetic and pharmacodynamic ex vivo endpoints: T cell expansion, persistence, biodistribution, cytokine release, and phenotype
Strong working understanding of tumor cell biology and strategies to overcome mechanisms of immune evasion
Hands-on expertise with ex vivo immunoprofiling using flow cytometry (high dimensional/multiparameter) and other technologies; specific expertise with assessing T cell function and phenotype
Excellent oral and written communication skills with experience leading the authorship of manuscripts; experience authoring regulatory documents a plus
Keen attention to detail with excellent organizational and record-keeping skills

*Candidates without a Ph.D. may be considered if they have commensurate experience

Valid through: 3/18/2021